Literature DB >> 25777777

Distribution of intestinal metaplasia as a predictor of gastric cancer development.

Satoki Shichijo1, Yoshihiro Hirata1, Kosuke Sakitani1, Shinzo Yamamoto1, Takako Serizawa1, Ryota Niikura1, Hirotsugu Watabe1, Shuntaro Yoshida1, Atsuo Yamada1, Yutaka Yamaji1, Tetsuo Ushiku2, Masashi Fukayama2, Kazuhiko Koike1.   

Abstract

BACKGROUND AND AIM: Helicobacter pylori, gastritis, and intestinal metaplasia (IM) are known risk factors for gastric cancer. In the present study, we conducted a cohort study to evaluate the predictive value of the distribution of IM for gastric cancer development.
METHODS: We conducted a retrospective cohort study at a university hospital. From June 1998 to December 2000, we assessed histological gastritis using biopsy specimens, one from the antrum and one from the corpus, from 1450 patients, among whom 729 revisited for follow-up endoscopy. Patients were classified into three groups according to the distribution of IM at initial endoscopy. IM group A had no IM, IM group B had IM in the antrum only, and IM group C had IM in the corpus. The development of gastric cancer was assessed by endoscopic examination.
RESULTS: The mean duration of follow-up was 6.7 ± 4.7 years. The cumulative incidence of gastric cancer at 5 years was 1.5% in total and 0.8%, 3.3%, and 2.7% in IM groups A, B, and C, respectively. The IM group was identified as an independent risk factor by multivariate analysis; compared with IM group A, hazard ratios were 3.6 (95% confidence interval [CI] 1.1-12.1) in IM group B and 3.8 (95% CI 1.01-14.1) in IM group C. In IM group C, the incidence of gastric cancer in patients who received eradication therapy was significantly lower than that in patients who did not receive (P = 0.021, log-rank).
CONCLUSION: IM is a good predictive marker for the development of gastric cancer.
© 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Helicobacter pylori; gastric cancer; intestinal metaplasia

Mesh:

Year:  2015        PMID: 25777777     DOI: 10.1111/jgh.12946

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

1.  Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis.

Authors:  Mitsushige Sugimoto; Masaki Murata; Yoshio Yamaoka
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

2.  Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study.

Authors:  Davide Campana; Davide Ravizza; Piero Ferolla; Antongiulio Faggiano; Franco Grimaldi; Manuela Albertelli; Claudio Ricci; Donatella Santini; Nicole Brighi; Nicola Fazio; Annamaria Colao; Diego Ferone; Paola Tomassetti
Journal:  Endocrine       Date:  2016-09-03       Impact factor: 3.633

Review 3.  The risk of diffuse-type gastric cancer following diagnosis with gastric precancerous lesions: a systematic review and meta-analysis.

Authors:  John E Wang; Sung Eun Kim; Bong Eun Lee; Sungho Park; Joo Ha Hwang; Robert J Huang
Journal:  Cancer Causes Control       Date:  2021-11-19       Impact factor: 2.506

Review 4.  Endoscopic surveillance of gastric cancers after Helicobacter pylori eradication.

Authors:  Masaaki Kobayashi; Yuichi Sato; Shuji Terai
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

5.  Gastric cancer diagnosed after Helicobacter pylori eradication in diabetes mellitus patients.

Authors:  Kosuke Sakitani; Yoshihiro Hirata; Nobumi Suzuki; Satoki Shichijo; Ayako Yanai; Takako Serizawa; Kei Sakamoto; Masao Akanuma; Shin Maeda; Yutaka Yamaji; Yasuhiko Iwamoto; Shoji Kawazu; Kazuhiko Koike
Journal:  BMC Gastroenterol       Date:  2015-10-21       Impact factor: 3.067

6.  Dysplasia in Gastric Mucosa and its Reporting Problems.

Authors:  Majlinda Ikonomi; Blerina Cela; Dhurata Tarifa
Journal:  Open Access Maced J Med Sci       Date:  2015-11-11

7.  Therapeutic or spontaneous Helicobacter pylori eradication can obscure magnifying narrow-band imaging of gastric tumors.

Authors:  Masaaki Kobayashi; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Yuichi Sato; Gen Watanabe; Yoichi Ajioka; Motoi Azumi; Kouhei Akazawa; Shuji Terai
Journal:  Endosc Int Open       Date:  2016-05-12

8.  Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.

Authors:  Bor-Shyang Sheu; Ming-Shiang Wu; Cheng-Tang Chiu; Jing-Chuan Lo; Deng-Chyang Wu; Jyh-Ming Liou; Chun-Ying Wu; Hsiu-Chi Cheng; Yi-Chia Lee; Ping-I Hsu; Chun-Chao Chang; Wei-Lun Chang; Jaw-Town Lin
Journal:  Helicobacter       Date:  2017-01-08       Impact factor: 5.753

9.  Application of Convolutional Neural Networks in the Diagnosis of Helicobacter pylori Infection Based on Endoscopic Images.

Authors:  Satoki Shichijo; Shuhei Nomura; Kazuharu Aoyama; Yoshitaka Nishikawa; Motoi Miura; Takahide Shinagawa; Hirotoshi Takiyama; Tetsuya Tanimoto; Soichiro Ishihara; Keigo Matsuo; Tomohiro Tada
Journal:  EBioMedicine       Date:  2017-10-16       Impact factor: 8.143

10.  Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication.

Authors:  Osamu Toyoshima; Yutaka Yamaji; Shuntaro Yoshida; Shuhei Matsumoto; Hiroharu Yamashita; Takamitsu Kanazawa; Keisuke Hata
Journal:  Surg Endosc       Date:  2016-09-07       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.